European Association for the Study of Diabetes (EASD) Annual Meeting 2025

Treatment with the GLP-1 receptor agonist semaglutide appears safe for patients initiating dialysis, as demonstrated in a pooled analysis presented at EASD 2025.

Combination treatment with cagrilintide and semaglutide significantly reduced body weight in patients with overweight or obesity and type 2 diabetes (T2D), according to the REDEFINE 2 trial presented at EASD 2025.

Once-weekly treatment with tirzepatide significantly reduces HbA_1c levels and BMI in children and adolescents with type 2 diabetes (T2D) compared with placebo, according to the SURPASS-PEDS trial presented at EASD 2025.

The old immunomodulatory drug antithymocyte globulin (ATG), administered at a low dose, can safely reduce the loss of beta-cell function in young people with recent-onset type 1 diabetes (T1D), as shown in the phase II MELD-ATG trial.

In adults with obesity but without diabetes, treatment with the oral small-molecule, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1RA) orforglipron yields substantial reductions in body weight, as shown in the phase III ATTAIN-1 trial.